CSL Seqirus Products
See the complete list of all products marketed by CSL Seqirus worldwide.
See Product ListSearch Results
327 results found-
With the approval of ARCT-154, CSL now offers an even more comprehensive portfolio of innovative vaccines that combat respiratory viral diseases.
https://www.csl.com/patients-public-health/vaccines/covid-19 -
Enhanced Influenza Vaccines Provide Essential Protection for Older Adults:
https://newsroom.csl.com/2025-10-21-Enhanced-Influenza-Vaccines-Provide-Essential-Protection-for-Older-Adults-CSL-Seqirus-Presents-New-Evidence-Supporting-Broader-Adoption-Across-Europe -
CSL Seqirus and Vaccine Industrial Company sign landmark Memorandum of Understanding with Ministry of Health to localize manufacturing of cell-based seasonal and pandemic influenza vaccines
https://newsroom.csl.com/2025-10-30-CSL-Seqirus-and-Vaccine-Industrial-Company-sign-landmark-Memorandum-of-Understanding-with-Ministry-of-Health-to-localize-manufacturing-of-cell-based-seasonal-and-pandemic-influenza-vaccines -
CSL Seqirus is a global influenza vaccine provider developing innovative solutions.
https://www.csl.com/patients-public-health/vaccines -
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults - Nov 28, 2023
https://newsroom.csl.com/2023-11-28-Japans-Ministry-of-Health,-Labour-and-Welfare-Approves-CSL-and-Arcturus-Therapeutics-ARCT-154,-the-first-Self-Amplifying-mRNA-vaccine-approved-for-COVID-in-adults -
17 October 2025 - CSL Seqirus, a business of CSL (ASX:CSL) today announced that it will be presenting 14 abstracts at the European Scientific Working group on Influenza conference (ESWI 20-23 October) highlighting the value of enhanced seasonal influenza vaccines and reinforcing the vital role they play in protecting public health.
https://newsroom.csl.com/2025-10-17-CSL-Seqirus-Presents-Latest-Research-Across-Leading-Seasonal-Influenza-Vaccine-Portfolio-at-ESWI-2025 -
CSL Seqirus employs both egg and cell-based manufacturing systems to ensure the availability of our influenza vaccines. Learn more about our optimised technology.
https://www.csl.com/we-are-csl/our-businesses-and-products/csl-seqirus/csl-seqirus-manufacturing/csl-seqirus-manufacturing-technologies -
World-class $1bn vaccine and antivenom manufacturing facility opens in Melbourne
https://newsroom.csl.com/2025-12-02-World-class-1bn-vaccine-and-antivenom-manufacturing-facility-opens-in-Melbourne -
ARCT ) is currently developing next generation mRNA vaccines.
https://newsroom.csl.com/2022-11-01-CSL-Enters-Licensing-Agreement-with-Arcturus-Therapeutics-for-Next-Generation-mRNA-Vaccine-Technology -
CSL's product portfolio focuses on innovation in new products, improved products and manufacturing expertise thereby ensuring our continued growth.
https://www.csl.com/research-and-development/product-pipeline